Endocrine Abstracts

Background and Aim: Type 2 diabetes mellitus (DM) treatment guidelines give preference to drugs with proven cardioprotective effect, which include sodium-glucose cotransporter type 2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). GLP-1RA are known to reduce the stroke risk. Data on SGLT-2i effect on the brain, in conditions of both acute and chronic cerebrovascular disorders, are less complete. The aim of our study was to evaluate the effect of h...